Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIX90M)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cannabinoid receptor 2 (CB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[2]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[3]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[4]
KHK-6188	DMF6CTI	Neuropathic pain	8E43.0	Phase 2	[5]
LY-2828360	DMO8IEZ	Pain	MG30-MG3Z	Phase 2	[5]
APD371	DM3XT5V	Crohn disease	DD70	Phase 2	[6]
S-777469	DMZGNOJ	Atopic dermatitis	EA80	Phase 2	[7]
842166X	DMOV0AP	Pain	MG30-MG3Z	Phase 2	[8]
Beta-caryophyllene	DM7583A	Pain	MG30-MG3Z	Phase 2	[9]
Vicasinabin	DMF16CU	Diabetic retinopathy	9B71.0	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
2	Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
3	Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
4	Company report (Gwpharm)
5	Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
8	The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
9	The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
10	Clinical pipeline report, company report or official report of Roche